N+1 Singer appointed as Nominated Adviser and Broker to LiDCO Group plc

LiDCO, a leading supplier of hemodynamic monitoring solutions, is pleased to announce the appointment of N+1 Singer as the Company’s Nominated Adviser and Broker with immediate effect.

LiDCO Group is the sixth client N+1 Singer has partnered with since the start of 2020, taking our total number of corporate clients to over 100 across AIM and the Main Market of the London Stock Exchange.

About LiDCO Group plc

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO’s products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies have shown that the optimisation of patients’ hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO’s computer-based technology, developed originally at St Thomas’ Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Ticker: LID
Market Cap: £14.6 million*
Website: Click here

*As at 11/03/2020

For more information on this news, please email us or call us on +44 (0)20 7496 3000.